Phase II Open-Label Study of Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemo
Sponsor study identifier
interventional
40
1 country
7
Study Start
December 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2004
Date type not reportedThis date has not been verified as actual or estimated.
December 21, 2004
Actual (reported)December 22, 2004
Actual (reported)March 2006
Date type not reportedThis date has not been verified as actual or estimated.
Proportion of patients with a confirmed tumor response at any time during the study.
Time to disease progression
Duration of tumor response
Pharmacokinetics (PK)
Immunogenicity
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Treatment programme
M200 (volociximab) in Combination with Dacarbazine (DTIC)
The registry describes a treatment programme. Individual components, doses and actual administration are not established by this entry.
View registry recordUniversity of Alabama at Birmingham-Comprehensive Cancer Ctr.
Birmingham, Alabama, 35294-3300, United States
Arizona Cancer Center
Tucson, Arizona, 85724, United States
UCLA School of Medicine
Los Angeles, California, 90095, United States
Cancer Institute Medical Group, Inc.
Santa Monica, California, 90404, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Palmetto Hematology Oncology, P.C.
Spartanburg, South Carolina, 29303, United States
MD Anderson Cancer Center
Steven J. O'Day, M.D.
Cancer Institute Medical Group, Inc.
John Kirkwood, M.D.
University of Pittsburgh
Agop Y. Bedikian, MD
M.D. Anderson Cancer Center
Antoni Ribas, MD
University of California, Los Angeles
First Submitted
December 21, 2004
First Posted
December 22, 2004
Study Start
December 2004
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
March 2006
Date type not reportedImmunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
Contact the study team to confirm eligibility.
Houston, Texas, 77030, United States
Colin P. Curran, M.D.
Palmetto Hematology Oncology, P.C.
Andres Forero, M.D.
University of Alabama at Birmingham
Lee Cranmer, M.D.
University of Arizona
This date has not been verified as actual or estimated.
Last Updated
August 5, 2008
Record last verified: 2008-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: